Top Markets
#1 Velas Velas +367.72%
#2 Gravity Gravity +48.67%
#3 Galxe Galxe +41.03%
#4 Audiera Audiera +35.08%
#5 Infinity Ground Infinity Ground +30.54%
#6 Nosana Nosana +30.00%
#7 Babylon Babylon +21.78%
#8 Aria.AI Aria.AI +21.37%
#9 Wiki Cat Wiki Cat +21.18%
#10 Fetch.ai Fetch.ai +20.36%
Coin of the day
Velas Velas
Settings
Language
ENGLISH
Currency
USD
Theme
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rank in Stocks #98
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Share Price
$38.05
Market Cap
$169.07B
Change (1 day)
0.22%
Change (1 year)
-50.38%
Country
DK
Trade Novo Nordisk A/S (NVO)

Category

Healthcare
Market Capitalization
Revenue
more
Earnings
Price History
P/E Ratio
P/S Ratio
P/B Ratio
Operating Margin
EPS
Stock Splits
Dividends
Dividend Yield
Shares Outstanding
Revenue for Novo Nordisk A/S (NVO)
Revenue in Dec 2025 TTM: $48.52B
According to Novo Nordisk A/S latest financial reports the company's current revenue (TTM) is $48.52B. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Novo Nordisk A/S from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -75.19%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -70.44%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -81.28%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -67.65%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B -88.68%
NL